Syndax Pharmaceuticals's three largest insider shareholders as of June 18, 2026 are Michael A Metzger (Chief Executive Officer, 491.69K shares), Dennis Podlesak (Director, 239.76K shares), Keith A. Goldan (Chief Financial Officer, 140.43K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Dennis Podlesak | - | 239,763 | 0 | 06 Feb, 2026 |
| Keith Katkin | - | 124,000 | 0 | 06 Feb, 2026 |
| Pierre Legault | - | 114,000 | 0 | 06 Feb, 2026 |
| Keith A. Goldan | Chief Financial Officer | 140,429 | 0 | 10 Feb, 2026 |
| Michael A Metzger | Chief Executive Officer | 491,690 | 0 | 10 Feb, 2026 |
| William Meury | - | 90,000 | 0 | 07 Feb, 2025 |
| Fabrice Egros | - | 32,000 | 0 | 03 Feb, 2022 |
| Martin H. Jr. Huber | - | 103,000 | 0 | 06 Feb, 2026 |
| Briggs Morrison | President, Head Of Rd | 34,836 | 0 | 09 Feb, 2024 |
| Michael L. Meyers | Svp, Chief Medical Officer | 23,280 | 0 | 03 Feb, 2022 |
| Jennifer Jarrett | - | 114,000 | 0 | 06 Feb, 2026 |
| Aleksandra Rizo | - | 49,000 | 0 | 06 Feb, 2026 |
| Neil Gallagher | President, Head Of Rd | 85,095 | 0 | 12 Feb, 2025 |
| Nicholas A.J. Botwood | Head Of Rd, Cmo | 95,165 | 0 | 06 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Feb, 2026 | Keith A. Goldan | Common Stock | D | 3,410 | $21.03 | 140,429 | D | S |
| 09 Feb, 2026 | Michael A Metzger | Common Stock | D | 17,159 | $21.03 | 491,690 | D | S |
| 04 Feb, 2026 | Michael A Metzger | Common Stock | A | 73,000 | $0.00 | 371,661 | D | A |
| 04 Feb, 2026 | Martin H. Jr. Huber | Common Stock | A | 24,000 | $0.00 | 103,000 | D | A |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Common Stock | A | 24,000 | $0.00 | 59,165 | D | A |
| 04 Feb, 2026 | Jennifer Jarrett | Common Stock | A | 24,000 | $0.00 | 114,000 | D | A |
| 30 Jan, 2026 | Keith A. Goldan | Common Stock | A | 1,219 | $8.48 | 93,671 | D | J |
| 04 Feb, 2026 | Pierre Legault | Common Stock | A | 24,000 | $0.00 | 114,000 | D | A |
| 04 Feb, 2026 | Aleksandra Rizo | Common Stock | A | 24,000 | $0.00 | 49,000 | D | A |
| 04 Feb, 2026 | Keith Katkin | Common Stock | A | 24,000 | $0.00 | 124,000 | D | A |
| 04 Feb, 2026 | Dennis Podlesak | Common Stock | A | 48,000 | $0.00 | 239,763 | D | A |
| 04 Feb, 2026 | Keith A. Goldan | Common Stock | A | 21,500 | $0.00 | 115,171 | D | A |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Common Stock | A | 36,000 | $0.00 | 95,165 | D | A |
| 04 Feb, 2026 | Michael A Metzger | Common Stock | A | 144,600 | $0.00 | 516,261 | D | A |
| 04 Feb, 2026 | Keith A. Goldan | Common Stock | A | 30,750 | $0.00 | 145,921 | D | A |
| 06 Feb, 2026 | Michael A Metzger | Common Stock | D | 7,412 | $20.62 | 508,849 | D | S |
| 04 Feb, 2026 | Nicholas A.J. Botwood | Stock Options (Right to buy) | A | 144,700 | $20.43 | 144,700 | D | A |
| 06 Feb, 2026 | Keith A. Goldan | Common Stock | D | 2,082 | $20.62 | 143,839 | D | S |
| 04 Feb, 2026 | Michael A Metzger | Stock Options (Right to buy) | A | 440,000 | $20.43 | 440,000 | D | A |
| 04 Feb, 2026 | Keith A. Goldan | Stock Options (Right to buy) | A | 118,000 | $20.43 | 118,000 | D | A |